Financial cost of osteoarthritis in France: The "COART" France study

Joint Bone Spine

Volumn 72, Issue 6, 2005, Pages 567-570

  Le Pen, Claude ^a   Reygrobellet, Camille ^a   Gérentes, Isabelle ^b  

^a Aremis Consultants   (France)

^b Laboratoires Negma   (France)

Author keywords

Aging; Cost of osteoarthritis; Healthcare costs; Symptomatic slow acting drugs for osteoarthritis

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TOPICAL AGENT;

AGED; ARTICLE; DOCUMENTATION; DRUG COST; ECONOMIC ASPECT; EMPLOYMENT; FRANCE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITAL COST; HUMAN; MEDICAL FEE; MEDICAL LEAVE; METHODOLOGY; OSTEOARTHRITIS; PRESCRIPTION; REIMBURSEMENT;

COST CONTROL; COST OF ILLNESS; FEMALE; FRANCE; HEALTH CARE COSTS; HUMANS; MALE; OSTEOARTHRITIS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 29244433028     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2005.01.011     Document Type: Article

References (17)

1. K. Walker-Bone, K. Javaid, N. Arden, and C. Cooper Medical management of osteoarthritis Br. Med. J. 321 2000 936 940
2. Assurance Maladie. http://www.ameli.fr/pdf/1049.pdf. Consulté le 20 août 2003.
3. Direction Générale de la Santé. http://www.sante. gouv.fr/htm/dossiers/losp/55arthrose.pdf. Consulté le 7 juillet 2003.
4. L. Auvray S. Dumesnil P. Le Fur Sant́, Soins et Protection Sociale en 2000 2001 CREDES Paris
5. J.Y. Reginster The prevalence and burden of osteoarthritis Rheumatol. 41 Suppl 2002 3 6
6. K.M. Jordan, N.K. Arden, M. Doherty, B. Bannwarth, J.W. Bijlsma, and P. Dieppe EULAR recommendations 2003: an evidence-based approach to the management of knee osteoarthritis: report of a task force for the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) Ann. Rheum. Dis. 62 2003 1145 1155
7. M. Hochberg Recommendations for the medical management of osteoarthritis of the hip and knee Arthritis Rheum. 43 2000 1905 1915
8. K. Walker-Bone, K. Javaid, N. Arden, and C. Cooper Medical management of osteoarthritis Br. Med. J. 321 2000 936 940
9. V. Sinkov, and T. Cymet Osteoarthritis: understanding the pathophysiology, genetics, and treatments J. Am. Med. Assoc. 95 2003 475 482
10. ̀re partie: le traitement pharmacologique Rev. Med. Interne 24 2002 183 188
11. M. Dougados, M. Nguyen, L. Berdah, B. Mazieres, E. Vignon, and M. Lequesne Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a 3-year, placebo-controlled trial Arthritis Rheum. 44 2001 2539 2547
12. E. Levy, A. Ferme, D. Perocheau, and I. Bono Socioeconomic costs of osteoarthritis in France Rev. Rhum. 60 1993 S63 S67
13. Direction des Statistiques et des Etudes de la CNAMTS. http://www.ameli.fr/pdf/948.pdf. Consulté le 20 août 2003.
14. Assurance Maladie. http://ameli.fr/pdf/928.pdf. Consulté le 20 août 2003.
15. R.L. Barrack Economics of revision total hip arthroplasty Clin. Orthop. 319 1995 209 214
16. Barrack RL. The economics of revision arthroplasty. Orthopedics 199;18:874-5.
17. C.J. Lavernia, M.K. Drakeford, A. Tsao, A. Gittelsohn, K.A. Krackow, and D.S. Hungerford Revision and primary hip and knee arthroplasty. A cost Analysis Clin. Orthop. 311 1995 136 141